Double maintains 3 strategies that include BIO - Bio-Rad Laboratories, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NEUE | -<0.01% | $61.16M | +29.25% | 0.00% |
| AQB | 0.02% | $2.87M | -53.40% | 0.00% |
| QNRX | 0.02% | $5.43M | -54.36% | 0.00% |
| PTGX | 0.06% | $3.11B | +45.16% | 0.00% |
| MCK | 0.12% | $90.90B | +24.44% | 0.39% |
| PPC | 0.12% | $10.79B | +32.45% | 0.00% |
| HUSA | -0.19% | $21.26M | -8.69% | 0.00% |
| LITB | -0.48% | $22.07M | -77.41% | 0.00% |
| VSA | 0.53% | $8.76M | -18.25% | 0.00% |
| UFI | 0.56% | $92.17M | -11.15% | 0.00% |
| VRCA | 0.75% | $55.59M | -91.95% | 0.00% |
| SOHU | -0.95% | $405.28M | -3.09% | 0.00% |
| K | -0.96% | $27.71B | +40.85% | 2.85% |
| PRPO | 1.09% | $16.51M | +118.40% | 0.00% |
| FTS | -1.21% | $23.99B | +23.37% | 3.67% |
| CCEC | -1.31% | $1.02B | +3.91% | 2.54% |
| TME | 1.43% | $13.46B | +33.33% | 0.95% |
| FYBR | 1.46% | $9.12B | +39.78% | 0.00% |
| GORV | 1.56% | $27.11M | -91.06% | 0.00% |
| AWK | -1.65% | $27.80B | +10.98% | 2.21% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPH | 64.65% | $730.32M | 0.4% |
| MOAT | 64.25% | $12.65B | 0.47% |
| FXH | 63.63% | $899.62M | 0.62% |
| FBT | 63.22% | $1.01B | 0.54% |
| BBH | 62.24% | $329.37M | 0.35% |
| GNOM | 61.56% | $44.38M | 0.5% |
| IBB | 61.50% | $5.28B | 0.45% |
| XHE | 60.24% | $166.19M | 0.35% |
| SMOT | 60.20% | $386.39M | 0.49% |
| VHT | 59.16% | $15.27B | 0.09% |
| FHLC | 59.08% | $2.43B | 0.084% |
| PBE | 58.95% | $223.86M | 0.58% |
| DSTL | 58.92% | $1.78B | 0.39% |
| IYH | 57.68% | $2.71B | 0.39% |
| FIW | 57.68% | $1.86B | 0.51% |
| IJJ | 57.04% | $7.69B | 0.18% |
| FLQM | 56.72% | $1.67B | 0.3% |
| IVOV | 56.62% | $928.93M | 0.1% |
| MDYV | 56.56% | $2.38B | 0.15% |
| JVAL | 56.29% | $515.03M | 0.12% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -10.46% | $24.29B | +35.36% | 1.09% |
| CME | -10.27% | $99.25B | +39.75% | 3.87% |
| CREG | -7.74% | $5.66M | -79.19% | 0.00% |
| EXC | -6.72% | $43.82B | +25.72% | 3.63% |
| VSTA | -6.17% | $341.66M | +42.00% | 0.00% |
| ED | -6.07% | $36.31B | +13.27% | 3.35% |
| MSIF | -4.65% | $756.27M | +33.83% | 7.70% |
| PULM | -3.36% | $24.14M | +230.50% | 0.00% |
| MKTX | -3.27% | $8.37B | +15.12% | 1.35% |
| TMUS | -2.95% | $274.22B | +34.19% | 1.37% |
| T | -2.36% | $207.81B | +53.45% | 3.83% |
| TEF | -2.11% | $30.02B | +27.27% | 6.13% |
| VHC | -2.10% | $48.79M | +87.46% | 0.00% |
| CNK | -2.09% | $3.46B | +40.52% | 0.53% |
| COR | -2.06% | $57.24B | +32.73% | 0.74% |
| KR | -2.00% | $47.17B | +41.48% | 1.81% |
| PM | -1.74% | $276.33B | +74.67% | 3.05% |
| AWK | -1.65% | $27.80B | +10.98% | 2.21% |
| CCEC | -1.31% | $1.02B | +3.91% | 2.54% |
| FTS | -1.21% | $23.99B | +23.37% | 3.67% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -41.15% | $99.49M | 0.59% |
| VIXY | -36.78% | $165.58M | 0.85% |
| IVOL | -34.60% | $348.25M | 1.02% |
| BTAL | -32.68% | $295.67M | 1.43% |
| CLIP | -21.98% | $1.51B | 0.07% |
| XONE | -21.25% | $585.85M | 0.03% |
| SHYM | -20.61% | $354.58M | 0.35% |
| FTSD | -20.41% | $231.68M | 0.25% |
| FXY | -18.95% | $820.31M | 0.4% |
| STPZ | -18.90% | $450.05M | 0.2% |
| SPTS | -18.53% | $5.77B | 0.03% |
| ULST | -16.77% | $658.54M | 0.2% |
| UTWO | -15.70% | $379.27M | 0.15% |
| LDUR | -15.14% | $929.45M | 0.5% |
| TPMN | -15.04% | $30.70M | 0.65% |
| IBTH | -15.00% | $1.60B | 0.07% |
| VTIP | -15.00% | $15.34B | 0.03% |
| IBTG | -14.83% | $1.92B | 0.07% |
| GSST | -14.79% | $919.83M | 0.16% |
| SCHO | -14.73% | $11.46B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MLN | 0.13% | $540.39M | 0.24% |
| ITM | 0.22% | $1.87B | 0.18% |
| DFIP | 0.23% | $920.81M | 0.11% |
| CANE | 0.23% | $10.58M | 0.29% |
| JMST | 0.36% | $4.06B | 0.18% |
| DFNM | 0.49% | $1.57B | 0.17% |
| XBIL | 0.54% | $783.84M | 0.15% |
| BNDX | 0.56% | $67.49B | 0.07% |
| FMHI | -0.66% | $753.22M | 0.7% |
| IBMP | 0.70% | $553.36M | 0.18% |
| OWNS | 0.77% | $130.26M | 0.3% |
| GSY | -0.78% | $2.86B | 0.22% |
| IGOV | 0.92% | $1.21B | 0.35% |
| IBND | -0.92% | $383.43M | 0.5% |
| SMMU | -0.96% | $889.48M | 0.35% |
| SHV | -0.96% | $20.67B | 0.15% |
| FLDR | 0.97% | $940.32M | 0.15% |
| IBTP | -1.00% | $143.32M | 0.07% |
| GOVT | 1.02% | $27.46B | 0.05% |
| TDTF | 1.18% | $845.57M | 0.18% |
Current Value
$249.161 Year Return
Current Value
$249.161 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| A | 71.51% | $34.22B | -4.24% | 1.01% |
| RVTY | 70.54% | $11.67B | -2.92% | 0.28% |
| TMO | 70.42% | $159.10B | -21.06% | 0.39% |
| TECH | 70.24% | $8.16B | -26.90% | 0.62% |
| DHR | 69.19% | $143.92B | -16.35% | 0.59% |
| MTD | 67.52% | $25.05B | -11.18% | 0.00% |
| BRKR | 64.82% | $6.35B | -32.02% | 0.48% |
| ILMN | 64.78% | $15.54B | -6.98% | 0.00% |
| RGEN | 63.15% | $7.10B | +5.24% | 0.00% |
| WAT | 62.22% | $21.25B | +25.50% | 0.00% |
| IQV | 61.79% | $28.13B | -21.62% | 0.00% |
| AVTR | 60.20% | $9.49B | -32.36% | 0.00% |
| QGEN | 57.42% | $10.44B | +15.16% | 0.00% |
| TXG | 57.14% | $1.51B | -36.09% | 0.00% |
| ZBRA | 56.51% | $16.04B | +1.76% | 0.00% |
| SWK | 54.49% | $10.89B | -11.31% | 4.66% |
| NVST | 53.68% | $3.39B | +22.52% | 0.00% |
| CC | 53.18% | $1.85B | -45.26% | 6.77% |
| TRU | 53.17% | $17.54B | +21.63% | 0.49% |
| SPB | 52.75% | $1.36B | -36.51% | 3.32% |
Yahoo
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
SeekingAlpha
During Q1 2025, the Harbor Mid Cap Fund returned -3.56%, underperforming its benchmark, the Russell Midcap Index, which returned -3.40%.
Yahoo
HERCULES, Calif., May 29, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025.
Finnhub
Presenter SpeechConor Noel McNamara Good afternoon, and welcome to the RBC Capital Markets 2025 Global Healthcare Conference. I'm Conor McNamara, the life science tools and diagnostics analyst at
SeekingAlpha
Parnassus Value Equity Fund (Investor Shares) returned -1.98% (net of fees) for the quarter, underperforming the Russell 1000 Value Indexâs 2.14%.
Yahoo
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
